157026-19-2

Basic information

• Product Name: 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE
• Synonyms: 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE;5-Bromo-2,3-diaminobenzotrifluoride 97%;5-BroMo-3-(trifluoroMethyl)-1,2-benzenediaMine;5-Bromo-3-(trifluoromethyl)benzene-1,2-diamine;5-broMo-3-(trifluoroMethyl)benzene-1;2-Amino-4-bromo-6-(trifluoromethyl)phenylamine;5-Bromo-2,3-diaminobenzotrifluoride97%
• CAS NO: 157026-19-2
• Molecular Formula: C₇H₆BrF₃N₂
• Molecular Weight: 255.0351496
• Mol File: 157026-19-2.mol

Chemical Properties

• Boiling Point: 268.801 °C at 760 mmHg
• Flash Point: 116.367 °C
• Appearance: /
• Density: 1.775 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.87±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE(157026-19-2)
• EPA Substance Registry System: 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE(157026-19-2)

Safety Data

• Hazardous Substances Data: 157026-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drug candidates.
Used in Organic Synthesis:
5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE is used as a reagent in organic synthesis, facilitating the creation of a wide range of organic compounds due to its reactive functional groups.
Used in Drug Discovery:
5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE is used as a modifying agent in drug discovery to alter protein structures, potentially leading to the identification of new therapeutic targets and the development of innovative treatments.
Used in Medicinal Chemistry Research and Development:
In the field of medicinal chemistry, 5-BROMO-2,3-DIAMINOBENZOTRIFLUORIDE is utilized in the research and development of new chemical compounds and pharmaceutical products, contributing to advancements in drug design and synthesis strategies.

InChI:InChI=1/C7H6BrF3N2/c8-3-1-4(7(9,10)11)6(13)5(12)2-3/h1-2H,12-13H2

Upstream product

• 157026-18-1 4-bromo-2-nitro-6-trilfuoromethyl-phenylamine 
• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 29124-62-7 N-(4-bromo-2-trifluoromethyl-phenyl)-acetamide 
• 179062-00-1 N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide 
• 105172-74-5 3-bromo-5-nitro-6-chlorobenzotrifluoride 

Downstream Products

• 1326309-48-1 4-{[6-cyclopropyl-1-methyl-4-(trifluoromethyl)-1H-benzimidazol-2-yl]carbonyl}-1-(trans-4-hydroxycyclohexyl)-2-piperazinone 
• 1352342-28-9 C₁₈H₁₃F₃N₂O₂ 
• 1352342-27-8 C₁₈H₁₂ClF₃N₂O₂ 
• 1352342-26-7 C₁₈H₁₃F₃N₂O₃ 

Relevant articles and documents

CYCLIC COMPOUNDS AND USES THEREOF

The invention generally relates to substituted benzothiophenyl, substituted benzothiazolyl, substituted indolyl and substituted benzoimidazolyl compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, inflammatory diseases or an autoimmune system disease (e.g., a T-Cell mediated autoimmune disesase).

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

An efficient synthetic process for scale-up production of 4,5-diamino-2- (trifluoromethyl)benzonitrile and 5-bromo-3-(trifluoromethyl)benzene-1,2-diamine

Starting from 4-amino-2-(trifluoromethyl)benzonitrile (6), an efficient and nonchromatographic process was developed for multihundred gram production of 4,5-diamino-2-(trifluoromethyl)- benzonitrile (1) in 73% yield and 98 HPLC area% purity over four synthetic steps. The same synthetic strategy was applied to 4-bromo-2-(trifluoromethyl)aniline (7) that afforded 5-bromo-3- (trifluoromethyl)benzene-1,2-diamine (5) in 81% overall yield and 99% HPLC area% purity.

2-perhalogenalkyl-substituted benzimidazoles, and their use as pesticides

The invention relates to new substituted benzimidazoles of the general formula (I) STR1 in which R1 represents hydrogen, alkyl or optionally substituted aryl, R2 represents hydroxyl, cyano, alkoxy or optionally substituted amino, R3 represents perhalogenoalkyl, and X1, X2, X3 and X4, independently of one another, in each case represent hydrogen, halogen, nitro or optionally substituted aryloxy, but with at least one of the substituents X1, X2, X3 or X4 being different from hydrogen, with the exception of the compound 1-cyanomethyl-2-trifluoromethyl-5,6-dichlorbenzimidazole, to their preparation and to their use as agents for combating pests.

Substituted benzimidazoles

The invention relates to new substituted benzimidazoles of the general formula (I) STR1 in which R1 represents hydrogen, alkyl, alkoxy or optionally substituted aryl, R2 represents hydroxyl, cyano or in each case optionally substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy, alkinyloxy, alkylthio, amino, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, dialkoxyphosphonyl, (hetero)aryl, (hetero)arylcarbonyl, (hetero)aryloxycarbonyl, (hetero)arylcarbonyloxy or (hetero)arylaminocarbonylaminocarbonyloxy, and R3 represents fluoroalkyl, X1, X2, X3 and X4 independently of one another in each case represent hydrogen, halogen, cyano, nitro, in each case optionally substituted alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl or cycloalkyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl or in each case optionally substituted aryl, aryloxy, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, but where at least one of the substituents X1, X2, X3 or X4 represents halogenoalkyl, with the exception of the chloromethyl radical, halogenoalkoxy, halogenoalkylthio, halogenoalkylsulphinyl, halogenoalkylsulphonyl or alkylsulphonyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl, or in each case optionally substituted aryl, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, their preparation and use as pesticides, and intermediates for their preparation.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Substituted benzimidazoles useful as pest control agents

The invention relates to new substituted benzimidazoles of the general formula (I) STR1 wherein R1, R2, R3, X1, X2, X3 and X4 have the meanings given in the disclosure, which are

Method of treating parastic protozoa with substituted benzimidazoles

The present invention relates to the use of benzimidazoles of the formula (I) STR1 in which X1, X2, X3, X4, R3 and R5 are described herein and these compounds are agents for combatting parasitic protozoa, in particular coccidia.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.